"Chronick\u00E1 myeloidn\u00ED leukemie (Od patogeneze k prvn\u00ED c\u00EDlen\u00E9 molekul\u00E1rn\u00ED l\u00E9\u010Db\u011B n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED u \u010Dlov\u011Bka)"@cs . . "Chronick\u00E1 myeloidn\u00ED leukemie (Od patogeneze k prvn\u00ED c\u00EDlen\u00E9 molekul\u00E1rn\u00ED l\u00E9\u010Db\u011B n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED u \u010Dlov\u011Bka)"@cs . "Transfuze a hematologie dnes" . . "Nau\u0161ov\u00E1, Jana" . "[1BDD6036DF62]" . . "Chronick\u00E1 myeloidn\u00ED leukemie (CML) je prvn\u00EDm lidsk\u00FDm n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm, u kter\u00E9ho byla jednozna\u010Dn\u011B prok\u00E1z\u00E1na souvislost n\u00E1dorov\u00E9ho fenotypu s chromozom\u00E1ln\u00ED translokac\u00ED (Filadelfsk\u00FD chromozom, Ph1+)(1) se specifick\u00FDm molekul\u00E1rn\u00EDm defektem - f\u00FAzn\u00EDm genem BCR-ABL. Ten k\u00F3duje Bcr-Abl tyrozinovou kin\u00E1zu (TK), kter\u00E1 konstitutivn\u011B aktivuje \u0159adu sign\u00E1ln\u00EDch drah (Ras, MAPK, PI3K atd.). D\u016Fsledkem je zv\u00FD\u0161en\u00E1 prolifera\u010Dn\u00ED aktivita myeloidn\u00EDch prekurzor\u016F, sn\u00ED\u017Een\u00ED jejich z\u00E1vislosti na r\u016Fstov\u00FDch faktorech, potla\u010Den\u00ED apopt\u00F3zy a alterace interakc\u00ED prekurzor\u016F a stromatu. Ztr\u00E1ta kontroly proliferace a expanze klon\u00E1ln\u00EDch krvetvorn\u00FDch progenitor\u016F odvozen\u00FDch od Ph1+ kmenov\u00E9 bu\u0148ky tvo\u0159\u00ED CML fenotyp. CML je prvn\u00ED neopl\u00E1zi\u00ED, u n\u00ED\u017E vedlo zji\u0161t\u011Bn\u00ED genotypu a patogeneze onemocn\u011Bn\u00ED k objeven\u00ED a klilnick\u00E9mu uplatn\u011Bn\u00ED c\u00EDlen\u00E9 molekul\u00E1rn\u00ED l\u00E9\u010Dby u \u010Dlov\u011Bka." . . "Chronic myeloid leukemia"@en . "Faber, Edgar" . "11" . . "Chronick\u00E1 myeloidn\u00ED leukemie (Od patogeneze k prvn\u00ED c\u00EDlen\u00E9 molekul\u00E1rn\u00ED l\u00E9\u010Db\u011B n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED u \u010Dlov\u011Bka)" . "Chronick\u00E1 myeloidn\u00ED leukemie (Od patogeneze k prvn\u00ED c\u00EDlen\u00E9 molekul\u00E1rn\u00ED l\u00E9\u010Db\u011B n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED u \u010Dlov\u011Bka)" . "Chronick\u00E1 myeloidn\u00ED leukemie (CML) je prvn\u00EDm lidsk\u00FDm n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm, u kter\u00E9ho byla jednozna\u010Dn\u011B prok\u00E1z\u00E1na souvislost n\u00E1dorov\u00E9ho fenotypu s chromozom\u00E1ln\u00ED translokac\u00ED (Filadelfsk\u00FD chromozom, Ph1+)(1) se specifick\u00FDm molekul\u00E1rn\u00EDm defektem - f\u00FAzn\u00EDm genem BCR-ABL. Ten k\u00F3duje Bcr-Abl tyrozinovou kin\u00E1zu (TK), kter\u00E1 konstitutivn\u011B aktivuje \u0159adu sign\u00E1ln\u00EDch drah (Ras, MAPK, PI3K atd.). D\u016Fsledkem je zv\u00FD\u0161en\u00E1 prolifera\u010Dn\u00ED aktivita myeloidn\u00EDch prekurzor\u016F, sn\u00ED\u017Een\u00ED jejich z\u00E1vislosti na r\u016Fstov\u00FDch faktorech, potla\u010Den\u00ED apopt\u00F3zy a alterace interakc\u00ED prekurzor\u016F a stromatu. Ztr\u00E1ta kontroly proliferace a expanze klon\u00E1ln\u00EDch krvetvorn\u00FDch progenitor\u016F odvozen\u00FDch od Ph1+ kmenov\u00E9 bu\u0148ky tvo\u0159\u00ED CML fenotyp. CML je prvn\u00ED neopl\u00E1zi\u00ED, u n\u00ED\u017E vedlo zji\u0161t\u011Bn\u00ED genotypu a patogeneze onemocn\u011Bn\u00ED k objeven\u00ED a klilnick\u00E9mu uplatn\u011Bn\u00ED c\u00EDlen\u00E9 molekul\u00E1rn\u00ED l\u00E9\u010Dby u \u010Dlov\u011Bka."@cs . "4"^^ . . "515327" . . . "CZ - \u010Cesk\u00E1 republika" . "5"^^ . "P(NC7490), P(NR7870), Z(MSM6198959205)" . . "1213-5763" . "We have treated with imatinib (IM) 146 CML patients to 1st April 2007. 17 patients were referred to other departments, 13 were treated before or after stem cell transplantation, one refused to continue with therapy, for two patients we lacked the full data for analysis and 11 patients with CML in chronic phase has been treated for less than 6 months. We report thus the experience with therapy in 102 patients ? 61 male and 41 women 17 to 78 yer old (median 52). Sokal risk was low in 36, intermediate in 40 and high in 24 patients. 80 patients started therapy with IM in chronic phase, 20 in acceleration and 2 in blastic phase. Interval diagnosis-therapy with IM ranged from 1 to 135 months (median 9). Follow up since diagnosis and start of IM was 7-207 months (median 46,5), resp. 0,36-74 months (median 34). 24 patients have additional cytogenetic abnormalities at the start of treatment. 28 patients were treated immediately after diagnosis, 4 were pre-treated with oral chemotherapy and 70 patients received"@en . . . . . "Divok\u00FD, Vladim\u00EDr" . "Chronic myeloid leukemia"@en . "RIV/61989592:15110/05:00001954!RIV09-MZ0-15110___" . "15110" . "4"^^ . "Jaro\u0161ov\u00E1, Marie" . . . . . "RIV/61989592:15110/05:00001954" . "Indr\u00E1k, Karel" . . "chronic myeloid leukemia; Philadelphia chromosome"@en . "S2" . . .